In summary, this study demonstrated that shikonin possesses anti-inflammatory activity, which involved the down-regulation of NO, PGE2, and TNF-α, as well as their major regulatory genes, via the suppression of crosstalk between LPS-induced NF-κB activation and ROS production
Anti-Cancer - Lithospermum erythrorhizon has long been used in traditional Asian medicine for the treatment of diseases including skin cancer. The in vitro anticancer studies viz. cell growth, cell cycle and apoptosis, and the expression of tumor regulating proteins were analyzed against B16F10 melanoma cells. LEH induced apoptosis in B16F10 cells by activation of caspase 3 and inducing sub-G1 cell cycle arrest. LEH exhibited both in vitro and in vivo anticancer activity. Shikonin derivatives in the LEH are responsible for the anticancer activity.
Shikonin (SK) has been isolated and identified as a key bioactive component in an herbal plant, Shikon (gromwell). In human breast cancer cells, we observed that treatment with SK inhibits tumor cell growth in estrogen receptor α (ERα)-positive, but not ERα-negative breast cancer cells. Finally, co-treatment with SK enhanced sensitivity of breast cancer cells to endocrine therapy. Collectively, our studies suggested that SK has a potential for antihormone therapy in ERα-positive breast cancer cells, and should serve as a target for new drug developments.
This study was aimed to investigate whether this chemical could also inhibit cell growth of lung cancer cells and, if so, works via what molecular mechanism. hese results indicate the potential and dose-related cytotoxic actions of shikonin on A549 lung cancer cells via p53-mediated cell fate pathways and raise shikonin a promising adjuvant chemotherapeutic agent for treatment of lung cancer in clinical practice.